 |
At SMART Biosciences we are engaged in a coordinated effort to discover and develop novel small-molecule therapeutics to treat major age-related illnesses, including Alzheimer's disease and various forms of cancer. Since our beginning in 2005, as a spin-off of Columbia University, we have been working to address significant unmet therapeutic needs in these large and rapidly growing markets. Through our affiliation with Columbia University, SMART holds exclusive worldwide licenses to valuable intellectual property.
Our scientists have identified several novel targets in two therapeutic areas that have the potential for new treatments in:
- Alzheimer's disease--a novel lipid target that modulates levels of neurotoxic beta-amyloid in the brain
- Cancer--novel targets that modulate p53 stability, increasing tumor-cell sensitivity to cytotoxic and radiation therapies
We believe our intellectual property and scientific rationale for future compound discovery offers a compelling opportunity for commercialization.
SMART is led by management and scientific advisory teams comprised of preeminent professionals distinguished in the worlds of academic science, pharmaceutical discovery, business/corporate development, finance and intellectual property law. The SMART Biosciences leadership team brings scientific rigor, business leadership, and innovation experience to our endeavors.
Our discovery and development strategy employs a unique-to-the-industry collaborative network of advanced business, academic and R&D interests throughout the United States and Asia. The company's management and scientific leadership team--James E. Foley, Ph.D., Sukwoo (Jeffrey) Oh, J.D., Tae-Wan Kim, Ph.D., Hahn-Jun Lee, Ph.D., and Wei Gu, Ph.D.--leverages deep ties and affiliations worldwide with key opinion leaders across academia and industry to drive a robust and efficient R&D program. We are currently exploiting opportunities for in-licensing, expanded business development, and discovery.
| |
